First Trust Nasdaq Pharmaceuticals ETF Price & Performance (FTXH)

The performance of biotech ETFs this year reveals significant disparities. First Trust NYSE Arca Biotechnology Index Fund leads with a 14.10% gain, while Tema Obesity & Cardiometabolic ETF trails with a 10.45% loss. These funds provide diversified exposure to biotech firms, balancing risks across the sector.1

Recent activity shows 23.8% of holdings in the First Trust Nasdaq Pharmaceuticals ETF experiencing insider purchases within six months. Notably, Charles River Laboratories, a key holding, saw directors acquire shares, signaling confidence in its future. Insider buying trends often reflect optimism about underlying company performance.2

New 25% tariffs on auto, semiconductor, and pharmaceutical imports pose challenges for ETFs in these sectors. Funds like Global X Autonomous & Electric Vehicles ETF and iShares Semiconductor ETF face potential volatility due to supply chain disruptions and increased costs, highlighting the impact of trade policies on investments.3